Syros Pharmaceuticals

EDITAS Medicine

The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.

Syndax

This biopharmaceutical company develops and commercialises targeted therapies for adult and paediatric patients with cancer and chronic graft-versus-host disease.

Oncopeptides AB

This biotech company develops targeted therapies for patients with difficult-to-treat hematological diseases, specifically focusing on multiple myeloma treatments.

Constellation Pharmaceuticals

This biopharmaceutical company develops small-molecule epigenetics therapies to treat patients with blood cancers and solid tumours.

Forma

This company develops small molecule therapies for patients with sickle cell disease and cancer.

Dania Therapeutics

The company develops small-molecule therapies targeting cancer metabolism to treat acute myeloid leukaemia and other life-threatening cancers for medical patients.

Bluebird Bio

This company develops and manufactures gene therapies for patients with severe genetic diseases, including sickle cell disease and beta-thalassaemia.

Blueprint Medicines

This biopharmaceutical company develops and commercialises kinase inhibitors for patients with systemic mastocytosis, gastrointestinal stromal tumours and other genomic-driven cancers.